CDCES UPDATED Exam Questions and
CORRECT Answers
DRI for pregnant women - Correct Answer- 175 g CHO, 71 g of protein, and 28 g of fiber
Postpartum DM Testing - Correct Answer- Guidelines recommend testing 4-12 weeks after
delivery using a 75-g OGTT.
Women who do not meet any of the diagnostic criteria for diabetes after pregnancy should
continue to be screened every 1-3 years.
DM Diagnosing Criteria - Correct Answer- FPG ≥126 mg/dL, with fasting defined as no
caloric intake for at least 8 hours
OR
2-hour plasma glucose ≥200 mg/dL during a 75-g oral glucose tolerance test (OGTT)
OR
A1C ≥6.5%
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random
plasma glucose ≥200 mg/dL
Metformin Contraindications - Correct Answer- eGFRs <30 mL/min/1.73 m2
A1C goal with CKD - Correct Answer- For individuals with CKD, an A1C goal of 7-7.9% is
recommended to prevent the progression of microvascular complications or CVD.
Pharmacologic treatment for pt with HF - Correct Answer- To improve cardiovascular (CV)
outcomes in type 2 diabetes and high cardiovascular risk, patients should consider an SGLT2
inhibitor or a GLP-1 receptor agonist. If HF predominates, then an SGLT2 inhibitor is
preferred. GLP-1 receptor agonists would be considered for HF if a patient were unable to
tolerate an SGLT2 inhibitor.
The SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have all demonstrated
reduction in hospitalization for HF (HHF).
, SGLT2 monitoring - Correct Answer- monitoring SCr and eGFR is advised
SGLT2 Side Effects - Correct Answer- SGLT2 inhibitors have demonstrated in their clinical
trials a statistically significant increase in genital mycotic infections, especially those related
to the Candida species.
There is an unclear risk of amputations that is not well understood because of varying reports
from clinical trials.
Although hyperkalemia is not common, it has been observed in some small trials with
canagliflozin. However, larger trials have not shown this effect. There is a risk of
hyperkalemia in patients predisposed to electrolyte abnormalities such as those with reduced
eGFR or those on medications such as ACE inhibitors or angiotensin receptor blockers that
may alter potassium levels.
Saxagliptin Contraindications - Correct Answer- Saxagliptin is not recommended in patients
who may have HF or are at risk for HF based on findings from the SAVOR-TIMI 53
(Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-
Thrombolysis in Myocardial Infarction)
Which DPP-4 inhibitor does not require renal dose adjustment? - Correct Answer- all of the
DPP-4 inhibitors require renal dose adjustment with the exception of linagliptin.
BMI Categories - Correct Answer- <18.5 underweight
18.5-24.9 normal
25-29.9 overweight
Class I: 30-34.9 kg/m2
Class II: 35-39.9 kg/m2
Class III: BMI ≥40 kg/m2, often referred to as morbidly obese
DSMES at 4 critical times - Correct Answer- 1) at diagnosis
2) annually for assessment of education, nutrition, and emotional needs
3) when new complicating factors influence self-management
4) when transitions in care occur
CORRECT Answers
DRI for pregnant women - Correct Answer- 175 g CHO, 71 g of protein, and 28 g of fiber
Postpartum DM Testing - Correct Answer- Guidelines recommend testing 4-12 weeks after
delivery using a 75-g OGTT.
Women who do not meet any of the diagnostic criteria for diabetes after pregnancy should
continue to be screened every 1-3 years.
DM Diagnosing Criteria - Correct Answer- FPG ≥126 mg/dL, with fasting defined as no
caloric intake for at least 8 hours
OR
2-hour plasma glucose ≥200 mg/dL during a 75-g oral glucose tolerance test (OGTT)
OR
A1C ≥6.5%
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random
plasma glucose ≥200 mg/dL
Metformin Contraindications - Correct Answer- eGFRs <30 mL/min/1.73 m2
A1C goal with CKD - Correct Answer- For individuals with CKD, an A1C goal of 7-7.9% is
recommended to prevent the progression of microvascular complications or CVD.
Pharmacologic treatment for pt with HF - Correct Answer- To improve cardiovascular (CV)
outcomes in type 2 diabetes and high cardiovascular risk, patients should consider an SGLT2
inhibitor or a GLP-1 receptor agonist. If HF predominates, then an SGLT2 inhibitor is
preferred. GLP-1 receptor agonists would be considered for HF if a patient were unable to
tolerate an SGLT2 inhibitor.
The SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have all demonstrated
reduction in hospitalization for HF (HHF).
, SGLT2 monitoring - Correct Answer- monitoring SCr and eGFR is advised
SGLT2 Side Effects - Correct Answer- SGLT2 inhibitors have demonstrated in their clinical
trials a statistically significant increase in genital mycotic infections, especially those related
to the Candida species.
There is an unclear risk of amputations that is not well understood because of varying reports
from clinical trials.
Although hyperkalemia is not common, it has been observed in some small trials with
canagliflozin. However, larger trials have not shown this effect. There is a risk of
hyperkalemia in patients predisposed to electrolyte abnormalities such as those with reduced
eGFR or those on medications such as ACE inhibitors or angiotensin receptor blockers that
may alter potassium levels.
Saxagliptin Contraindications - Correct Answer- Saxagliptin is not recommended in patients
who may have HF or are at risk for HF based on findings from the SAVOR-TIMI 53
(Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-
Thrombolysis in Myocardial Infarction)
Which DPP-4 inhibitor does not require renal dose adjustment? - Correct Answer- all of the
DPP-4 inhibitors require renal dose adjustment with the exception of linagliptin.
BMI Categories - Correct Answer- <18.5 underweight
18.5-24.9 normal
25-29.9 overweight
Class I: 30-34.9 kg/m2
Class II: 35-39.9 kg/m2
Class III: BMI ≥40 kg/m2, often referred to as morbidly obese
DSMES at 4 critical times - Correct Answer- 1) at diagnosis
2) annually for assessment of education, nutrition, and emotional needs
3) when new complicating factors influence self-management
4) when transitions in care occur
